Skip to search formSkip to main contentSkip to account menu

risedronic acid

Known as: Acido risedronico, Acid, Risedronic, Acidum risedronicum 
National Institutes of Health

Related topics

Related topics

7 relations

Narrower (3)

ActonelRisedronaterisedronate sodium
Atelvia 35 MG Delayed Release Oral Tablet Once-a-Week Packrisedronate sodium 30 MG Oral Tabletrisedronate sodium 5 MG Oral Tablet [Actonel]{4 (risedronate sodium 35 MG Oral Tablet) } Pack

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Anti-osteoporotic treatments in France: initiation, persistence and switches over 6 years of follow-up
SummaryLimited information is available on anti-osteoporotic treatment initiation patterns in France. In 2006–2013, the most… 
2016
2016
Adherence to alendronic or risedronic acid treatment, combined or not to calcium and vitamin D, and related determinants in Italian patients with osteoporosis
Purpose Osteoporosis is a chronic disease and an important health and social burden due to its worldwide prevalence. Literature… 
2015
2015
On-cartridge derivatization coupled with solid-phase extraction for the ultra-sensitive determination of minodronic acid in human plasma by LC-MS/MS method.
Highly Cited
2010
Highly Cited
2010
Synthesis, chiral high performance liquid chromatographic resolution and enantiospecific activity of a potent new geranylgeranyl transferase inhibitor, 2-hydroxy-3-imidazo[1,2-a]pyridin-3-yl-2…
3-(3-Pyridyl)-2-hydroxy-2-phosphonopropanoic acid (3-PEHPC, 1) is a phosphonocarboxylate (PC) analogue of 2-(3-pyridyl)-1… 
2009
2009
A sensitive post-column photochemical derivatization/fluorimetric detection system for HPLC determination of bisphosphonates.
Review
2007
Review
2007
Zoledronic acid: a review of its use in the treatment of Paget's disease of bone.
The third-generation, nitrogen-containing bisphosphonate zoledronic acid (Aclasta) is approved in the EU for the treatment of… 
Review
2005
Review
2005
Pharmacological Management of Severe Postmenopausal Osteoporosis
The most devastating consequence of osteoporosis is bone fracture, particularly at the vertebral or femoral level. As defined by… 
Review
2002
Review
2002
Modern Therapy for Paget’s Disease of Bone
There has been a dramatic change in the therapeutic approach to patients with Paget’s disease of bone over the last 40 years. In… 
Review
2000
Review
2000
Preventing Fractures in Postmenopausal Women with Osteoporosis
The evidence from randomised, controlled trials of the ability of antiresorptive treatments to reduce the risk of fractures in… 
Review
1998
Review
1998
Corticosteroid-Induced Osteoporosis
Corticosteroid-induced osteoporosis is the leading cause of secondary osteoporosis and a significant cause of morbidity in both… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)